CD274 and neoplasm: In RCC, tumor-derived PD-L1 binds PD-1 on CD8+ T cells, recruiting SLC11A1 and inactivating ZAP70 and PI3K/AKT signaling, while CTLA−4 competes for B7 ligands on APCs to prevent costimulation (20–24).